<DOC>
	<DOCNO>NCT00622336</DOCNO>
	<brief_summary>The study evaluate safety Lenalidomide monotherapy participant advance multiple myeloma discontinue treatment combination thalidomide plus high-dose dexamethasone high-dose dexamethasone alone study Thal-MM-003 , CC-5013-MM-009 CC-5013-MM-010 due development document disease progression inability tolerate low dose regimen per previous protocol thalidomide and/or high-dose dexamethasone without grade 3 4 toxicity .</brief_summary>
	<brief_title>A Companion Study Studies THAL-MM-003 , CC-5013-MM-009 , CC-5013-MM-010 Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Age ≥ 18 year time signing informed consent form . Able adhere study visit schedule protocol requirement Participants multiple myeloma enrol either THALMM003 , CC5013MM009 , CC5013MM010 discontinue study therapy thalidomide highdose dexamethasone highdose dexamethasone alone due : documented disease progression OR inability tolerate low dose regimen allow previous protocol without grade 3 4 toxicity . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0,1,2 Recovery thalidomide dexamethasonerelated toxicity ≤ grade 2 ( NCI CTC ) Females childbearing potential ( FCBP ) must agree use two method contraception Prior development ≥ grade 2 allergic reaction/hypersensitivity prior development grade ≥ 3 rash desquamation take thalidomide National Cancer Institute Common toxicity Criteria ( NCI CTC ) Use standard/experimental antimyeloma therapy within 28 day randomization use experimental nondrug therapy within 56 day initiation drug treatment Any serious medical condition , laboratory abnormality , psychiatric illness prevent participant signing informed consent form place participant unacceptable risk toxicity he/she participate study . Pregnant lactate female . Prior therapy CC5013 ; prior history malignancy , multiple myeloma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) , unless subject free disease ≥ 5 year More 4 month elapse since last dose study drug administer study Tal MM003 , CC5013MM009 , CC5013MM010 Absolute neutrophil count ( ANC ) &lt; 1,000cells/mm^3 ( 1.0 X 10^9/L ) Platelet count &lt; 75,000/mm^3 ( 30 X 10^9/L ) &lt; 50 % bone marrow nucleate cell plasma cell ; Platelet count &lt; 30,000/mm^3 ( 30 X 10^9/L ) &lt; 50 % bone marrow nucleate cell plasma cell Serum creatinine &gt; 2.5mg/dL ; serum SGOT/AST SGPT/ALT x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0mg/d/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revlimid</keyword>
</DOC>